The association between polypharmacy and dementia: A nested case-control study based on a 12-year longitudinal cohort database in South Korea

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Park, Hae Young ^a   Park, Ji Won ^a   Song, Hong Ji ^b   Sohn, Hyun Soon ^c   Kwon, Jin Won ^a  

^a Kyungpook National University   (South Korea)

^b Hallym University   (South Korea)

^c CHA University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; EXPOSURE; FEMALE; HEMIPLEGIA; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PEPTIC ULCER; POLYPHARMACY; SOUTH KOREA; ADVERSE EFFECTS; ALZHEIMER DISEASE; CASE CONTROL STUDY; INAPPROPRIATE PRESCRIBING; MULTIPLE SCLEROSIS; ODDS RATIO; RISK FACTOR; VERY ELDERLY;

CHOLINERGIC RECEPTOR BLOCKING AGENT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CHOLINERGIC ANTAGONISTS; DEMENTIA; HUMANS; INAPPROPRIATE PRESCRIBING; LONGITUDINAL STUDIES; MULTIPLE SCLEROSIS; ODDS RATIO; POLYPHARMACY; REPUBLIC OF KOREA; RISK FACTORS;

EID: 85008641999     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169463     Document Type: Article

References (57)

1. National Institute on Aging/National Institute of Health. Gloabal health and aging. World Health Organization, 2011 NIH Publication no. 11-7737.
2. Korean Statisticcal Information Service. Estimated future population.http://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT-1B01B01&vw-cd=&list-id=&scrId=&seqNo=&lang-mode=ko&obj-var-id=&itm-id=&conn-path=K1&path=.
3. YH Jung. A study on the effective chronic disease management. Korea Institute for Health and Social Affairs: Korea Institute for Health and Social Affairs, 2013 Contract No.: 2013-31-19.
4. Martin Prince EA, Maeèlenn Guerchet, Matthew Prina, . World Alzheimer Report 2014; Dementia and Risk Reduction- An analysis of protecive and modifiable factors. Alzheimer's Disease International (ADI), London, 2014.
5. Peng D. The global burden of demential worldwide. January 13-14, 2011, Geneva, Switzerland IAGG/WHO/SFGG Workshop Health promotion program on prevention of late onset dementia: 2011.
6. World Health Organization. Ageing and Health Technical Report Vol.5: A Glossary of Terms for Community Health Care and Services for Older.
7. Gillette C, Prunty L, Wolcott J, Broedel-Zaugg K. A new lexicon for polypharmacy: Implications for research, practice, and education. Research in social & administrative pharmacy: RSAP. 2015; 11 (3):468-71.
8. Turner JP, Jamsen KM, Shakib S, Singhal N, Prowse R, Bell JS. Polypharmacy cut-points in older people with cancer: how many medications are too many? Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2015.
9. Frazier SC. Health outcomes and polypharmacy in elderly individuals: An integrated literature review. Journal of gerontological nursing. 2005; 31(9):4-11. PMID: 16190007.
10. Franchi C, Marcucci M, Mannucci PM, Tettamanti M, Pasina L, Fortino I, et al. Changes in clinical outcomes for community-dwelling older people exposed to incident chronic polypharmacy: A comparison between 2001 and 2009. Pharmacoepidemiology and drug safety. 2016; 25(2):204-11. doi:10.1002/pds.3938 PMID: 26687829.
11. Fried TR, O'Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health outcomes associated with polypharmacy in community-dwelling older adults: A systematic review. Journal of the American Geriatrics Society. 2014; 62(12):2261-72. doi:10.1111/jgs.13153 PMID: 25516023.
12. Wang R, Chen L, Fan L, Gao D, Liang Z, He J, et al. Incidence and Effects of Polypharmacy on Clinical Outcome among Patients Aged 80-: A Five-Year Follow-Up Study. PloS one. 2015; 10(11):e0142123. doi:10.1371/journal.pone.0142123 PMID: 26554710.
13. Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications to combat polypharmacy. Therapeutic advances in drug safety. 2015; 6(6):212-33. doi:10.1177/2042098615613984 PMID: 26668713.
14. Marengoni A, Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. Bmj. 2015; 350:h1059. doi:10.1136/bmj.h1059 PMID: 25761379.
15. Fried TR, Tinetti ME, Iannone L, O'Leary JR, Towle V, Van Ness PH. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. Archives of internal medicine. 2011; 171(20):1854-6. doi:10.1001/archinternmed.2011.424 PMID: 21949032.
16. Patterson SM, Cadogan CA, Kerse N, Cardwell CR, Bradley MC, Ryan C, et al. Interventions to improve the appropriate use of polypharmacy for older people. The Cochrane database of systematic reviews. 2014; 10:CD008165.
17. Hajjar ER, Hanlon JT, Artz MB, Lindblad CI, Pieper CF, Sloane RJ, et al. Adverse drug reaction risk factors in older outpatients. The American journal of geriatric pharmacotherapy. 2003; 1(2):82-9. PMID: 15555470.
18. Gallacher KI, Batty GD, McLean G, Mercer SW, Guthrie B, May CR, et al. Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1, 424, 378 patients in Scotland: implications for treatment burden. BMC medicine. 2014; 12:151. doi:10.1186/s12916-014-0151-0 PMID: 25280748.
19. Lau DT, Mercaldo ND, Harris AT, Trittschuh E, Shega J, Weintraub S. Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia. Alzheimer disease and associated disorders. 2010; 24(1):56-63. doi:10.1097/WAD.0b013e31819d6ec9 PMID: 19561441.
20. Lai SW, Lin CH, Liao KF, Su LT, Sung FC, Lin CC. Association between polypharmacy and dementia in older people: A population-based case-control study in Taiwan. Geriatrics & gerontology international. 2012; 12(3):491-8.
21. Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort Profile: The National Health Insurance Service- National Sample Cohort (NHIS-NSC), South Korea. International journal of epidemiology. 2016.
22. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical care. 2005; 43(11):1130-9. PMID: 16224307.
23. By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2015; 63(11):2227-46. doi:10.1111/jgs.13702 PMID: 26446832.
24. Draper B, Karmel R, Gibson D, Peut A, Anderson P. The Hospital Dementia Services Project: Age differences in hospital stays for older people with and without dementia. International psychogeriatrics. 2011; 23(10):1649-58. Epub 2011/09/10. doi:10.1017/S1041610211001694 PMID: 21902861.
25. Park HY, Ryu HN, Shim MK, Sohn HS, Kwon JW. Prescribed drugs and polypharmacy in healthcare service users in South Korea: An analysis based on National Health Insurance Claims data. International journal of clinical pharmacology and therapeutics. 2016; 54(5):369-77. Epub 2016/03/24. doi:10.5414/CP202484 PMID: 27007996.
26. Dohoo IR, Ducrot C, Fourichon C, Donald A, Hurnik D. An overview of techniques for dealing with large numbers of independent variables in epidemiologic studies. Preventive veterinary medicine. 1997; 29 (3):221-39. Epub 1997/01/01. PMID: 9234406.
27. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: A prospective cohort study. JAMA internal medicine. 2015; 175 (3):401-7. Epub 2015/01/27. doi:10.1001/jamainternmed.2014.7663 PMID: 25621434.
28. Lebedev AV, Beyer MK, Fritze F, Westman E, Ballard C, Aarsland D. Cortical changes associated with depression and antidepressant use in Alzheimer and Lewy body dementia: An MRI surface-based morphometric study. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. 2014; 22(1):4-13 e1.
29. Zhong G, Wang Y, Zhang Y, Zhao Y. Association between Benzodiazepine Use and Dementia: A Meta-Analysis. PloS one. 2015; 10(5):e0127836. Epub 2015/05/29. doi:10.1371/journal.pone.0127836 PMID: 26016483.
30. Boustani M, Hall KS, Lane KA, Aljadhey H, Gao S, Unverzagt F, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. Journal of the American Geriatrics Society. 2007; 55(8):1248-53. Epub 2007/07/31. doi:10.1111/j.1532-5415.2007.01270.x PMID: 17661965.
31. Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. European archives of psychiatry and clinical neuroscience. 2015; 265(5):419-28. doi:10.1007/s00406-014-0554-0 PMID: 25341874.
32. Dublin S, Walker RL, Gray SL, Hubbard RA, Anderson ML, Yu O, et al. Prescription Opioids and Risk of Dementia or Cognitive Decline: A Prospective Cohort Study. Journal of the American Geriatrics Society. 2015; 63(8):1519-26. doi:10.1111/jgs.13562 PMID: 26289681.
33. Gupta M, Singh R, Singh K, Lehl SS. Reversible dementia and gait disturbance as a result of polypharmacy. BMJ case reports. 2013; 2013. Epub 2013/03/28.
34. Evans MD, Shinar R, Yaari R. Reversible dementia and gait disturbance after prolonged use of valproic acid. Seizure. 2011; 20(6):509-11. Epub 2011/03/26. doi:10.1016/j.seizure.2011.02.009 PMID: 21435910.
35. LoGiudice D, Watson R. Dementia in older people: An update. Internal medicine journal. 2014; 44 (11):1066-73. doi:10.1111/imj.12572 PMID: 25367725.
36. Wolkowitz OM, Lupien SJ, Bigler E, Levin RB, Canick J. The "steroid dementia syndrome": An unrecognized complication of glucocorticoid treatment. Annals of the New York Academy of Sciences. 2004; 1032:191-4. Epub 2005/01/29. doi:10.1196/annals.1314.018 PMID: 15677408.
37. Wolkowitz OM, Lupien SJ, Bigler ED. The "steroid dementia syndrome": A possible model of human glucocorticoid neurotoxicity. Neurocase. 2007; 13(3):189-200. Epub 2007/09/06. doi:10.1080/13554790701475468 PMID: 17786779.
38. Jyrkka J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiology and drug safety. 2011; 20(5):514-22. doi:10.1002/pds.2116 PMID: 21308855.
39. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. Journal of clinical epidemiology. 2012; 65(9):989-95. doi:10.1016/j.jclinepi.2012.02.018 PMID: 22742913.
40. Brown J. The use and misuse of short cognitive tests in the diagnosis of dementia. Journal of neurology, neurosurgery, and psychiatry. 2015; 86(6):680-5. Epub 2014/11/21. doi:10.1136/jnnp-2014-309086 PMID: 25411547.
41. Perrotta M, Lembo G, Carnevale D. Hypertension and Dementia: Epidemiological and Experimental Evidence Revealing a Detrimental Relationship. International journal of molecular sciences. 2016;17 (3). Epub 2016/03/24.
42. Kim KW, Park JH, Kim MH, Kim MD, Kim BJ, Kim SK, et al. A nationwide survey on the prevalence of dementia and mild cognitive impairment in South Korea. Journal of Alzheimer's disease: JAD. 2011; 23 (2):281-91. Epub 2010/12/24. doi:10.3233/JAD-2010-101221 PMID: 21178286.
43. KW Kim. A study on the Demented Elderly Seoul National University Bundang Hospital; 2011. http://www.google.co.kr/url?url=http://www.prism.go.kr/homepage/researchCommon/downloadResearchAttachFile.do%3Bjsessionid%DCD0D96D5D3BD1B1123E20C698BC923E.node02%3Fwork-key%3D001%26file-Type%3DCPR%26seq-no%3D001%26pdf-conv-yn%3DY%26research-id%3D1351000-201000126&rct=j&frm=1&q=&esrc=s&sa=U&ved=0ahUKEwiSpIvx4KPNAhUBHJQKHZp-DgUQFgglMAM&sig2=5sGD5Je42mvet4Pjahim9Q&usg=AFQjCNG-iMoLrKmwR3iUpK6JFI-EqFTK1Q.
44. Viswanathan H, Bharmal M, Thomas J 3rd. Prevalence and correlates of potentially inappropriate prescribing among ambulatory older patients in the year 2001: comparison of three explicit criteria. Clinical therapeutics. 2005; 27(1):88-99. Epub 2005/03/15. doi:10.1016/j.clinthera.2005.01.009 PMID: 15763610.
45. Hwang HJ, Kim SH, Lee KS. Potentially Inappropriate Medications in the Elderly in Korean Long-Term Care Facilities. Drugsreal world outcomes. 2015; 2(4):355-61. Epub 2015/12/23. doi:10.1007/s40801-015-0046-1 PMID: 26689669.
46. Alhmoud E, Khalifa S, Bahi AA. Prevalence and predictors of potentially inappropriate medications among home care elderly patients in Qatar. International journal of clinical pharmacy. 2015; 37(5):815- 21. doi:10.1007/s11096-015-0125-0 PMID: 25986290.
47. Andersen F, Viitanen M, Halvorsen DS, Straume B, Engstad TA. Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the dementia study in northern Norway. BMC geriatrics. 2011; 11:58. Epub 2011/10/06. doi:10.1186/1471-2318-11-58 PMID: 21970467.
48. Montastruc F, Gardette V, Cantet C, Piau A, Lapeyre-Mestre M, Vellas B, et al. Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs! European journal of clinical pharmacology. 2013; 69(8):1589-97. Epub 2013/04/17. doi:10.1007/s00228-013-1506-8 PMID: 23588564.
49. Lau DT, Mercaldo ND, Shega JW, Rademaker A, Weintraub S. Functional decline associated with polypharmacy and potentially inappropriate medications in community-dwelling older adults with dementia. American journal of Alzheimer's disease and other dementias. 2011; 26(8):606-15. doi:10.1177/1533317511432734 PMID: 22207646.
50. Sakakibara M, Igarashi A, Takase Y, Kamei H, Nabeshima T. Effects of Prescription Drug Reduction on Quality of Life in Community-Dwelling Patients with Dementia. Journal of pharmacy & pharmaceutical sciences: A publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2015; 18(5):705-12. Epub 2015/12/17.
51. Onder G, Liperoti R, Foebel A, Fialova D, Topinkova E, van der Roest HG, et al. Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: Results from the SHELTER study. Journal of the American Medical Directors Association. 2013; 14(6):450.e7-12. Epub 2013/05/08.
52. Fields J, Go JT, Schulze KS. Pill Properties that Cause Dysphagia and Treatment Failure. Current therapeutic research, clinical and experimental. 2015; 77:79-82. Epub 2015/11/07. doi:10.1016/j.curtheres.2015.08.002 PMID: 26543509.
53. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: The process of deprescribing. JAMA internal medicine. 2015; 175(5):827-34. doi:10.1001/jamainternmed.2015.0324 PMID: 25798731.
54. Garcia-Ptacek S, Faxen-Irving G, Cermakova P, Eriksdotter M, Religa D. Body mass index in dementia. European journal of clinical nutrition. 2014; 68(11):1204-9. Epub 2014/10/02. doi:10.1038/ejcn.2014.199 PMID: 25271014.
55. Pedditizi E, Peters R, Beckett N. The risk of overweight/obesity in mid-life and late life for the development of dementia: A systematic review and meta-Analysis of longitudinal studies. Age and ageing. 2016; 45(1):14-21. Epub 2016/01/15. doi:10.1093/ageing/afv151 PMID: 26764391.
56. Kim KN, Y J. Predictors of Health-related Quality of Life in Korean Elderly: Based on the 2013 Korea National Health and Nutrition Examination Survey. Asia-pacific Journal of Multimedia Services Convergent with Art, Humanities, and Sociology. 2015; 5:197-205.
57. Grandner MA, Schopfer EA, Sands-Lincoln M, Jackson N, Malhotra A. Relationship between sleep duration and body mass index depends on age. Obesity (Silver Spring, Md). 2015; 23(12):2491-8. Epub 2016/01/05.